Advertisement
Advertisement
AUTL
Autolus Therapeutics plc - ADR
1.71
USDSponsored
+0.11
+6.87%
May 13, 15:38 UTC -4
Closed
Pre-Market
1.74
+0.03
+1.75%
AUTL Earnings Reports
Positive Surprise Ratio
AUTL beat 14 of 28 last estimates.
50%
Next Report
Today BMO
Date of Next Report
May 14, 2026
Estimate for Q1 26 (Revenue/ EPS)
$26.68M
/-$0.26
Implied change from Q4 25 (Revenue/ EPS)
+9.86%
/-23.53%
Implied change from Q1 25 (Revenue/ EPS)
+197.08%
/--
Autolus Therapeutics plc - ADR earnings per share and revenue
On Mar 27, 2026, AUTL reported earnings of -0.34 USD per share (EPS) for Q4 25, missing the estimate of -0.27 USD, resulting in a -25.18% surprise. Revenue reached 24.29 million, compared to an expected 24.97 million, with a -2.73% difference. The market reacted with a -8.67% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.26 USD, with revenue projected to reach 26.68 million USD, implying an decrease of -23.53% EPS, and increase of 9.86% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Autolus Therapeutics plc - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Autolus Therapeutics plc - ADR reported EPS of -$0.34, missing estimates by -25.18%, and revenue of $24.29M, -2.73% below expectations.
How did the market react to Autolus Therapeutics plc - ADR's Q4 2025 earnings?
The stock price moved down -8.67%, changed from $1.50 before the earnings release to $1.37 the day after.
When is Autolus Therapeutics plc - ADR expected to report next?
The next earning report is scheduled for May 14, 2026.
What are the forecasts for Autolus Therapeutics plc - ADR's next earnings report?
Based on 6
analysts, Autolus Therapeutics plc - ADR is expected to report EPS of -$0.26 and revenue of $26.68M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement